$GLSI

Greenwich LifeSciences has received a 'buy' rating following the release of promising open-label data and a recent patent claim. The open-label trial results are expected to bolster investor confidence in the company's vaccine candidate. Analysts highlight the potential for significant upside as the patent claim may provide a competitive edge. This combination of positive data and legal positioning is likely to attract more institutional investors. Overall, the sentiment around Greenwich LifeSciences is turning bullish.